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Abstract
ASSESSMENT OF ORAL HUMAN PAPILLOMAVIRUS IN PEDIATRIC AND ADULT
PATIENTS WITHIN A MULTI-ETHNIC CLINIC POPULATION

By

Melissa Kornhaber

Dr. Karl Kingsley, Examination Committee Chair
Professor of Biomedical Sciences
Director of Student Research
University of Nevada, Las Vegas
School of Dental Medicine
Introduction: Human papillomavirus (HPV) encompasses a large family of oncogenic viruses
responsible for increasing rates of both cervical and oral cancer, particularly among minority and
low-income populations. Although this represents an increasingly significant public health risk,
few studies have screened for oral HPV within Nevada. Based upon this information, the primary
objective of this study was to provide a temporal analysis of oral HPV screening among a
primarily low-income, minority patient population.

Methods: This retrospective analysis was reviewed and approved by the Institutional Review
Board (IRB). In brief, unstimulated saliva samples were previously obtained from clinical patient
volunteers that provided Informed Consent and Pediatric Assent (if applicable). DNA was
isolated and screened using spectrophotometry for quality (A260:A280 ratio > 1.70) and quantity
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(concentration > 100 ng). Validated qPCR primers were used to screen repository samples for
high-risk HPV strains HPV16 and HPV18.

Results: A total of N=930 samples were identified for this study, which involved n=555 samples
from adults and n=375 from pediatric patients treated between 2011 and 2019. Demographic
analysis revealed nearly equal distribution between males and females with most derived from
non-White (minority) patients. qPCR screening revealed an overall increase in high-risk HPV of
3.17-fold from 5.7% in 2011 to 18.1% in 2019 and a coefficient of determination or R2 = 0.764,
suggesting a strong, positive correlation between more recent sample years and HPV-positive
results, which was observed among both pediatric (R2=0.671) and adult (R2=0.971) patients. In
addition, although the average age among adult patients increased over time - a significant
decrease was observed among pediatric patients from an average of 16.0 years to 14.81 years.

Conclusions: These data suggest temporal changes and positive increases in the prevalence of
oral HPV among both the pediatric and adult patient samples taken from this clinic population.
These data are important as considerations are made regarding which HPV vaccination education
and awareness programs are introduced and the specific populations most likely to benefit from
these interventions.

Key words: Human papillomavirus (HPV), high-risk HPV, oral screening, oral cancer, qPCR
screening
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Chapter 1: Introduction
Background and Significance
The human papillomavirus (HPV) includes a large family of closely related DNA viruses
capable of causing cancer in many cells and tissues, including cervical and oral cancers [1,2].
These HPV strains are generally divided into high- and low-risk categories, based upon their
propensity to drive oncogenesis in various tissues and organs [3-5]. This includes HPV16 and
HPV18, which are responsible for the majority of cervical cancers – as well as the vast majority
of oral HPV infections worldwide [6-8].

Many epidemiologic studies have found the incidence and prevalence of oral cancer may be
increasing over time among specific population subgroups, including minorities and low-income
patients in both developing and developed countries [9-11]. For example, these studies have
revealed public health disparities and significantly increased risk in oral cancer among these
subgroups in Asia, particularly in developing nations that include India, Pakistan, Bangladesh
and Sri Lanka where public health literacy is low and prevention resources are limited [12].
Although smoking and tobacco or betel quid chewing have been identified as the most prevalent
risk factors, an increasing percentage of these cancers have now been confirmed as HPV-positive
with growing public health concern about the relatively low levels of HPV vaccination –
especially in India [12,13]. In addition, another large developing country with an identified
public health problem involving rapidly increasing cases of HPV-positive oral and esophageal
cancers is northwestern China, where age-adjusted mortality has reached 150 per 100,000 –
compared with rates of 2.5 per 100,000 in the United States (U.S.) [12,14].
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In other developing areas of the world, such as sub-Saharan Africa, a growing public health
concern has been identified with increasing rates and cases of HPV-mediated diseases including
cervical and oral cancer - even among more developed countries such as South Africa [15]. In
addition, other systematic reviews of HPV infection (both cervical and oral) in areas such as
South America, have revealed increasingly high rates among emerging and developing countries
with large populations, such as Brazil [16]. These combined data suggest these trends are of
particular concern for public health and oral healthcare providers.

Additional epidemiologic studies have found similar results in other developed countries,
including many in Europe and the U.S. [17,18]. In particular, developed countries with advanced
healthcare systems including Sweden and the U.S. have demonstrated decreased rates of
smoking but increasing rates of oral cancer specifically related to HPV16 [17]. This evidence
suggests that as many as three-fourths of oral cancers are HPV-positive, which could be
prevented with current HPV vaccination [18,19]. According to recent studies, high-risk HPV
may be implicated in the majority of oropharyngeal cancers in the U.S., with estimates of
incidence increasing 225% between 1988 and 2004 [18-20].

Although these efforts have produced significant data for public health officials to address, few
studies have focused more specifically on these subgroups within the population of Nevada
[21,22]. For example, a limited number of studies have evaluated increased risk for some
cancers, such as breast and oral cancer in Nevada [23-26]. However, only a few studies have
evaluated the risk and prevalence of oral HPV among these groups in this area [27-29]. More
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studies are needed to increase our understanding of oral HPV prevalence and the oral
epidemiology associated with these infections.

Based upon this information, the objective of this study was to determine any changes in
prevalence of oral HPV over time among the pediatric and adult patients within a dental school
clinic population using an existing repository.

Research Question
1. What is the prevalence of oral HPV among the pediatric patient population at UNLVSDM over time?
a. Null hypothesis (H0): Oral HPV prevalence does not change over time among
pediatric patients
b. Alternative hypothesis (HA): Oral HPV prevalence does change over time among
pediatric patients
2. What is the prevalence of oral HPV among the adult patient population at UNLV-SDM
over time?
a. Null hypothesis (H0): Oral HPV prevalence does not change over time among
adult patients
b. Alternative hypothesis (HA): Oral HPV prevalence does change over time among
adult patients

Approval
This retrospective study of existing samples and data was reviewed and approved by the
Institutional Review Board (IRB) and the Office for the Protection of Research Subjects (OPRS)
at the University of Nevada, Las Vegas (UNLV) under Protocol 1619329-1 titled “Retrospective
Analysis of Oral Health Status of Dental Population” on July 24, 2020 and [1717625-1]
3

“Retrospective Analysis of Microbial Prevalence from DNA Isolated from Saliva Samples
Originally Obtained from the University of Nevada, Las Vegas (UNLV) School of Dental
Medicine (SDM) Pediatric and Clinical Population” on March 21, 2021 as Exempt under Federal
Regulation 45 CFR 46. The original collection protocol was 1305-4466M "The Prevalence of
Oral Microbes in Saliva from the UNLV School of Dental Medicine Pediatric and Adult Clinical
Population" approved May 30, 2014.

Research Design
Original Collection Protocol
Under the original study protocols, all samples in the original studies were collected from
voluntary participants who were asked to provide informed consent if over the age of 18 years
old. For children, both pediatric assent and informed consent from a parent or guardian was
required for study participation. Inclusion criteria included patients of record at UNLV-SDM,
agreement to voluntary, unpaid study participation, and provision of informed consent and
pediatric assent when applicable. Exclusion criteria included any person not a patient of record at
UNLV-SDM, any person that did not wish to participate in the voluntary, unpaid study, and any
patient that declined to provide either informed consent (over 18 years old) or pediatric assent
(under 18 years old).

In brief, patients at the beginning of their clinic visit were provided with sterile collection tubes
and asked to provide up to 1.0 mL of unstimulated saliva. Each sample was marked with a
randomly generated, non-duplicated identification number to prevent any patient identifying
information from being associated with any specific sample. Basic demographic information was
4

collected at the time of sampling, which included age, sex, race or ethnicity. No other clinical or
demographic information was collected at the time. Each sample was then transferred to a
biomedical science laboratory for storage at -20°C and subsequent processing. Long-term storage
was done at -80°C.

DNA Isolation
Each sample was thawed and DNA isolated using the GenomicPrep DNA isolation kit from
Amersham Biosciences (Buckinghamshire, UK), as previously described [27-29]. In brief, equal
volumes of sample (500uL) were added to Phenol:Chloroform and centrifuged using an
Eppendorf 5424 microcentrifuge (Hamburg, Germany) at 10,000 x g at 4°C for fifteen minutes to
achieve phase separation. The upper (aqueous) phase was transferred to a sterile tube and nucleic
acids were precipitated with the addition of an equal volume of isopropanol and centrifuged for
ten minutes. The pellet was subsequently washed with molecular grade ethanol and centrifuged
for five minutes. The supernatant was aspirated and discarded and the pellet was resuspended in
nuclease-free water.

Quantitative and Qualitative DNA Assessment
Quality and quantity were assessed using a NanoDrop 2000 spectrophotometer from
ThermoFisher Scientific and readings at A260 and A280 nm. Absorbance readings were
automatically converted into ng/uL of double stranded DNA, based on the known conversion
factor of 1 unit of optical density for 50 ng/uL at A260 nm using the NanoDrop automated
software. The purity (or amount of protein contamination) was determined by the NanoDrop and
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evaluation of the ratio of absorbance readings at both A260 nm and A280 nm, due to the
differences in absorbance between nucleic acids and protein at these wavelengths.

Real-time qPCR Screening
Samples (N=930) from pediatric (N=470) and adult (N=460) patients that met the minimum
acceptable criteria for screening, including purity (A260:A280 ratio > 1.70) and concentration (>
[100 ng/uL]) were screened in triplicate using validated primers for both oral high-risk strains of
HPV (HPV16, HPV18) using Glyceraldehyde-3-Phosphate Dehydrogenase or GAPDH as the
positive qPCR control, as previously described [27-29]. In brief, each reaction was performed
using the ABsolute SYBR green mix from ThermoFisher Scientific, which consisted of 2X
ABsolute SYBR green master mix (12.5 uL), Forward primer at 10 uM (1.5 uL), Reverse primer
at 10 uM (1.5 uL), DNA sample (1.0 ng) and up to 8.0 uL of nuclease-free water. Each reaction
was run for 15 minutes at 95°C for enzyme activation, followed by 40 cycles of denaturation for
15 seconds at 95°C, annealing at the primer-specific temperature for 30 seconds and extension at
72°C for an additional 30 seconds.

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
GAPDH forward, 5′-ATCTTCCAGGAGCGAGATCC-3′; 20 nt, 55% GC, Tm: 66 °C
GAPDH reverse, 5′-ACCACTGACACGTTGGCAGT-3′; 20 nt, 55% GC, Tm: 70 °C
Optimal PCR Tm: 61°C

HPV16
Forward primer: 5’-ATGTTTCAGGACCCACAGGA-3’; 20nt; 50% GC: Tm=66°C
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Reverse primer 5’-CCTCACGTCGCAGTAACTGT-3’; 20nt; 55% Tm=67°C
Optimal PCR Tm: 65°C

HPV18
Forward primer: 5’-ATGGCGCGCTTTGAGGATCC-3’; 20nt; 60% GC: Tm=71°C
Reverse primer: 5’-GCATGCGGTATACTGTCTCT-3’; 20nt; 50% GC: Tm=64°C
Optimal PCR Tm: 63°C

Statistical Analysis
Demographic information regarding patient sex, age and race/ethnicity as self-reported (White or
Minority, with subgroups matching the clinic patient intake forms listed as Hispanic, Black,
Asian and Other) were compiled in Microsoft Excel (Redmond, WA). Descriptive statistics for
overall age average and range, percentage of males and females, as well as racial and ethnic
categories were compiled. Comparisons between the study sample and the overall clinic
demographics were made using Chi square ( 2) analysis and reported with degrees of freedom
(d.f.) and the resulting p-value (using

=0.05 level of significance), which is appropriate for

categorical, non-parametric data. Two-tailed t-tests were used to determine any differences
between the average age of study samples and the overall age of the adult or pediatric clinic
populations, which is appropriate for continuous, parametric data analysis.

Data regarding HPV screening (HPV positive, HPV negative) and high-risk HPV strains
(HPV16, HPV18) were compiled and presented as descriptive statistics for each year (2011 –
2019). Coefficient of determination or R2 was used to assess the significance and strength of
7

correlation between sampling year and the presence or absence of HPV-positive samples (weak
positive correlation: 0 – 0.299, moderate positive correlation 0.3 – 0.699, strong positive
correlation 0.7 – 1.0).
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Abstract
Introduction: Human papillomavirus (HPV) encompasses a large family of oncogenic viruses
responsible for increasing rates of both cervical and oral cancer, particularly among minority and
low-income populations. Although this represents an increasingly significant public health risk,
few studies have screened for oral HPV within Nevada. Based upon this information, the primary
objective of this study was to provide a temporal analysis of oral HPV screening among a
primarily low-income, minority patient population.

Methods: This retrospective analysis was reviewed and approved by the Institutional Review
Board (IRB). In brief, unstimulated saliva samples were previously obtained from clinical patient
volunteers that provided Informed Consent and Pediatric Assent (if applicable). DNA was
isolated and screened using spectrophotometry for quality (A260:A280 ratio > 1.70) and quantity
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(concentration > 100 ng). Validated qPCR primers were used to screen repository samples for
high-risk HPV strains HPV16 and HPV18.

Results: A total of N=930 samples were identified for this study, which involved n=555 samples
from adults and n=375 from pediatric patients treated between 2011 and 2019. Demographic
analysis revealed nearly equal distribution between males and females with most derived from
non-White (minority) patients. qPCR screening revealed an overall increase in high-risk HPV of
3.17-fold from 5.7% in 2011 to 18.1% in 2019 and a coefficient of determination or R2 = 0.764,
suggesting a strong, positive correlation between more recent sample years and HPV-positive
results, which was observed among both pediatric (R2=0.671) and adult (R2=0.971) patients. In
addition, although the average age among adult patients increased over time - a significant
decrease was observed among pediatric patients from an average of 16.0 years to 14.81 years.

Conclusions: These data suggest temporal changes and positive increases in the prevalence of
oral HPV among both the pediatric and adult patient samples taken from this clinic population.
These data are important as considerations are made regarding which HPV vaccination education
and awareness programs are introduced and the specific populations most likely to benefit from
these interventions.

Key words: Human papillomavirus (HPV), high-risk HPV, oral screening, oral cancer, qPCR
screening
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Introduction
The human papillomavirus (HPV) includes a large family of closely related DNA viruses
capable of causing cancer in many cells and tissues, including cervical and oral cancers [1,2].
These HPV strains are generally divided into high- and low-risk categories, based upon their
propensity to drive oncogenesis in various tissues and organs [3-5]. This includes HPV16 and
HPV18, which are responsible for the majority of cervical cancers – as well as the vast majority
of oral HPV infections worldwide [6-8].

Many epidemiologic studies have found the incidence and prevalence of oral cancer may be
increasing over time among specific population subgroups, including minorities and low-income
patients in both developing and developed countries [9-11]. For example, these studies have
revealed public health disparities and significantly increased risk in oral cancer among these
subgroups in Asia, particularly in developing nations that include India, Pakistan, Bangladesh
and Sri Lanka where public health literacy is low and prevention resources are limited [12].
Although smoking and tobacco or betel quid chewing have been identified as the most prevalent
risk factors, an increasing percentage of these cancers have now been confirmed as HPV-positive
with growing public health concern about the relatively low levels of HPV vaccination –
especially in India [12,13]. In addition, another large developing country with an identified
public health problem involving rapidly increasing cases of HPV-positive oral and esophageal
cancers is northwestern China, where age-adjusted mortality has reached 150 per 100,000 –
compared with rates of 2.5 per 100,000 in the United States (U.S.) [12,14].

In other developing areas of the world, such as sub-Saharan Africa, a growing public health
concern has been identified with increasing rates and cases of HPV-mediated diseases including
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cervical and oral cancer - even among more developed countries such as South Africa [15]. In
addition, other systematic reviews of HPV infection (both cervical and oral) in areas such as
South America, have revealed increasingly high rates among emerging and developing countries
with large populations, such as Brazil [16]. These combined data suggest these trends are of
particular concern for public health and oral healthcare providers.

Additional epidemiologic studies have found similar results in other developed countries,
including many in Europe and the U.S. [17,18]. In particular, developed countries with advanced
healthcare systems including Sweden and the U.S. have demonstrated decreased rates of
smoking but increasing rates of oral cancer specifically related to HPV16 [17]. This evidence
suggests that as many as three-fourths of oral cancers are HPV-positive, which could be
prevented with current HPV vaccination [18,19]. According to recent studies, high-risk HPV
may be implicated in the majority of oropharyngeal cancers in the U.S., with estimates of
incidence increasing 225% between 1988 and 2004 [18-20].

Although these efforts have produced significant data for public health officials to address, few
studies have focused more specifically on these subgroups within the population of Nevada
[21,22]. For example, a limited number of studies have evaluated increased risk for some
cancers, such as breast and oral cancer in Nevada [23-26]. However, only a few studies have
evaluated the risk and prevalence of oral HPV among these groups in this area [27-29]. More
studies are needed to increase our understanding of oral HPV prevalence and the oral
epidemiology associated with these infections.
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Based upon this information, the objective of this study was to determine any changes in
prevalence of oral HPV over time among the pediatric and adult patients within a dental school
clinic population using an existing repository.

Methodology
Study approval
This retrospective study of existing samples and data was reviewed and approved by the
Institutional Review Board (IRB) and the Office for the Protection of Research Subjects (OPRS)
at the University of Nevada, Las Vegas (UNLV) under Protocol 1619329-1 titled “Retrospective
Analysis of Oral Health Status of Dental Population” on July 24, 2020 and [1717625-1]
“Retrospective Analysis of Microbial Prevalence from DNA Isolated from Saliva Samples
Originally Obtained from the University of Nevada, Las Vegas (UNLV) School of Dental
Medicine (SDM) Pediatric and Clinical Population” on March 21, 2021 as Exempt under Federal
Regulation 45 CFR 46. The original collection protocol was 1305-4466M "The Prevalence of
Oral Microbes in Saliva from the UNLV School of Dental Medicine Pediatric and Adult Clinical
Population" approved May 30, 2014.

Original collection protocol
All samples in the original studies were collected from voluntary participants who were asked to
provide informed consent if over the age of 18 years old. For children, both pediatric assent and
informed consent from a parent or guardian was required for study participation. Inclusion
criteria included patients of record at UNLV-SDM, agreement to voluntary, unpaid study
participation, and provision of informed consent and pediatric assent when applicable. Exclusion
criteria included any person not a patient of record at UNLV-SDM, any person that did not wish
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to participate in the voluntary, unpaid study, and any patient that declined to provide either
informed consent (over 18 years old) or pediatric assent (under 18 years old).

In brief, patients at the beginning of their clinic visit were provided with sterile collection tubes
and asked to provide up to 1.0 mL of unstimulated saliva. Each sample was marked with a
randomly generated, non-duplicated identification number to prevent any patient identifying
information from being associated with any specific sample. Basic demographic information was
collected at the time of sampling, which included age, sex, race or ethnicity. No other clinical or
demographic information was collected at the time. Each sample was then transferred to a
biomedical science laboratory for storage at -20°C and subsequent processing. Long-term storage
was done at -80°C.

DNA isolation
Each sample was thawed and DNA isolated using the GenomicPrep DNA isolation kit from
Amersham Biosciences (Buckinghamshire, UK), as previously described [27-29]. In brief, equal
volumes of sample (500uL) were added to Phenol:Chloroform and centrifuged using an
Eppendorf 5424 microcentrifuge (Hamburg, Germany) at 10,000 x g at 4°C for fifteen minutes to
achieve phase separation. The upper (aqueous) phase was transferred to a sterile tube and nucleic
acids were precipitated with the addition of an equal volume of isopropanol and centrifuged for
ten minutes. The pellet was subsequently washed with molecular grade ethanol and centrifuged
for five minutes. The supernatant was aspirated and discarded and the pellet was resuspended in
nuclease-free water.
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Quantitative and qualitative DNA assessment
Quality and quantity were assessed using a NanoDrop 2000 spectrophotometer from
ThermoFisher Scientific and readings at A260 and A280 nm. Absorbance readings were
automatically converted into ng/uL of double stranded DNA, based on the known conversion
factor of 1 unit of optical density for 50 ng/uL at A260 nm using the NanoDrop automated
software. The purity (or amount of protein contamination) was determined by the NanoDrop and
evaluation of the ratio of absorbance readings at both A260 nm and A280 nm, due to the
differences in absorbance between nucleic acids and protein at these wavelengths.

Real-time qPCR screening
Samples (N=930) from pediatric (N=470) and adult (N=460) patients that met the minimum
acceptable criteria for screening, including purity (A260:A280 ratio > 1.70) and concentration (>
[100 ng/uL]) were screened in triplicate using validated primers for both oral high-risk strains of
HPV (HPV16, HPV18) using Glyceraldehyde-3-Phosphate Dehydrogenase or GAPDH as the
positive qPCR control, as previously described [27-29]. In brief, each reaction was performed
using the ABsolute SYBR green mix from ThermoFisher Scientific, which consisted of 2X
ABsolute SYBR green master mix (12.5 uL), Forward primer at 10 uM (1.5 uL), Reverse primer
at 10 uM (1.5 uL), DNA sample (1.0 ng) and up to 8.0 uL of nuclease-free water. Each reaction
was run for 15 minutes at 95°C for enzyme activation, followed by 40 cycles of denaturation for
15 seconds at 95°C, annealing at the primer-specific temperature for 30 seconds and extension at
72°C for an additional 30 seconds.

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)

21

GAPDH forward, 5′-ATCTTCCAGGAGCGAGATCC-3′; 20 nt, 55% GC, Tm: 66 °C
GAPDH reverse, 5′-ACCACTGACACGTTGGCAGT-3′; 20 nt, 55% GC, Tm: 70 °C
Optimal PCR Tm: 61°C

HPV16
Forward primer: 5’-ATGTTTCAGGACCCACAGGA-3’; 20nt; 50% GC: Tm=66°C
Reverse primer 5’-CCTCACGTCGCAGTAACTGT-3’; 20nt; 55% Tm=67°C
Optimal PCR Tm: 65°C

HPV18
Forward primer: 5’-ATGGCGCGCTTTGAGGATCC-3’; 20nt; 60% GC: Tm=71°C
Reverse primer: 5’-GCATGCGGTATACTGTCTCT-3’; 20nt; 50% GC: Tm=64°C
Optimal PCR Tm: 63°C

Statistical analysis
Demographic information regarding patient sex, age and race/ethnicity as self-reported (White or
Minority, with subgroups matching the clinic patient intake forms listed as Hispanic, Black,
Asian and Other) were compiled in Microsoft Excel (Redmond, WA). Descriptive statistics for
overall age average and range, percentage of males and females, as well as racial and ethnic
categories were compiled. Comparisons between the study sample and the overall clinic
demographics were made using Chi square ( 2) analysis and reported with degrees of freedom
(d.f.) and the resulting p-value (using

=0.05 level of significance), which is appropriate for

categorical, non-parametric data. Two-tailed t-tests were used to determine any differences
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between the average age of study samples and the overall age of the adult or pediatric clinic
populations, which is appropriate for continuous, parametric data analysis.

Data regarding HPV screening (HPV positive, HPV negative) and high-risk HPV strains
(HPV16, HPV18) were compiled and presented as descriptive statistics for each year (2011 –
2019). Coefficient of determination or R2 was used to assess the significance and strength of
correlation between sampling year and the presence or absence of HPV-positive samples (weak
positive correlation: 0 – 0.299, moderate positive correlation 0.3 – 0.699, strong positive
correlation 0.7 – 1.0).

Results
This retrospective study involved the retrieval and study of N=930 pediatric (N=470) and adult
(N=460) patient samples (Table 1). More specifically, the percentage of study samples from
adult males and females was nearly equal (48.5%, 51.5%, respectively), which was not
significantly different from the percentage of males and females from the overall clinical
population, p=0.1290. However, the percentage of adult samples from racial and ethnic
minorities was significantly different with lower percentages of minorities (59.3%) and
Hispanics in particular (23.4%) than in the clinic population (65.4%, 58.6%, respectively),
p=0.001. In addition, the proportion of study samples from White (40.7%), Black (19.5%) and
Asian (16.4%) adults was higher than has been observed in the clinic population (34.6%, 10.2%
and 6.6%, respectively). The average sample age for adults was 42.08 years (range 18 - 88 yrs.),
which was not significantly younger than the average age for adult clinic patients of 42.31 years
(range 18 - 89 yrs.), p=0.411.
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The analysis of pediatric samples revealed the percentage of pediatric males and females was
nearly equal (46.4%, 53.6%, respectively), which was not significantly different from the overall
percentage of males and females from the pediatric clinical population, p=0.6123. In addition,
the percentage of pediatric samples from racial and ethnic minorities was not significantly
different between the study sample (78.4%) and the pediatric clinic population (75.3%),
p=0.4884. However, more in-depth analysis revealed a lower percentage of Hispanics in the
study sample (31.5%) and higher percentages of Blacks (27.2%) and Asians (20%) compared
with the pediatric clinic population (52.1%, 11.8%, and 11.4%, respectively). The average
sample age for pediatric patients was 13.03 years (range 5 - 17 yrs.), which was significantly
different than the average overall age for pediatric clinic patients of 10.44 years (range 0 - 17
yrs.), p=0.019.

Table 1. Study Sample demographics
Demographics

Study Sample

Clinic

N=269 (48.5%)

50.9%

Statistical Analysis

Sex
Adult - Males

2=2.305, d.f.=1
p = 0.1290

Adult - Females

N=286 (51.5%)

49.1%

N=226 (40.7%)

34.6%

Race / Ethnicity
White
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2=16.444, d.f.=1

p = 0.0001
Minority

N=329 (59.3%)

65.4%

Hispanic

N=130 (23.4%)

58.6%

Black

N=108 (19.5%)

10.2%

Asian/Other

N=91 (16.4%)

6.6%

42.80 yrs.

42.31 yrs.

Two-tailed t-test

Median

42 yrs.

41 yrs.

p = 0.411

Range

18 - 88 yrs.

18 - 89 yrs.

N=174 (46.4%)

47.2%

Age
Average/Range

Sex
Pediatric - Males

2=0.257, d.f.=1
p = 0.6123

Pediatric - Females

N=201 (53.6%)

52.8%

N=81 (21.6%)

24.7%

Race / Ethnicity
White

2=0.480, d.f.=1
p = 0.4884
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Minority

N=294 (78.4%)

75.3%

Hispanic

N=118 (31.5%)

52.1%

Black

N=102 (27.2%)

11.8%

Asian/Other

N=75 (20.0%)

11.4%

13.03 yrs.

10.44 yrs.

Two-tailed t-test

Median

12 yrs.

10 yrs.

p = 0.019

Range

5 - 17 yrs.

0 - 17 yrs.

Age
Average/Range

To determine if the samples had sufficient quantity and quality for qPCR analysis, all samples
were screened using spectrophotometric analysis (Table 2). These data demonstrated that all
pediatric samples had sufficient concentrations of DNA (average 218.4 ng/uL) and purity
(average A260:A280 = 1.74) for subsequent qPCR screening. In addition, adult samples also
demonstrated sufficient concentrations of DNA (average 334.1 ng/uL) and purity (average
A260:A280 = 1.76) for further processing and screening.
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Table 2. Analysis of study sample DNA.
Study sample

DNA concentration

DNA purity (A260:A80)

Pediatric samples

Average: 218.4 ng/uL +/- 88.2

Average: 1.74

N=470

Range: 110 – 631.1 ng/uL

Range: 1.70 – 1.79

Adult samples

Average: 334.1 ng/uL +/- 91.1

Average: 1.76

N=460

Range: 135 – 815.1 ng/uL

Range: 1.70 – 1.81

To determine if this population experienced any changes in prevalence of oral HPV over time,
HPV screening results for the study sample, including both pediatric and adult patients, were
analyzed and graphed (Figure 1). More specifically, this analysis demonstrates that the
proportion of samples testing positive for high-risk HPV increased from 5.7% in 2011 to 18.1%
in 2019, an increase of 3.17-fold over this time period. More in-depth analysis revealed the
coefficient of determination or R2 = 0.764, which suggests a positive correlation between the
more recent sample years and HPV-positivity.
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Figure 1. Change in prevalence of high-risk oral HPV over time. Analysis of both pediatric and
adult patients revealed an increase in high-risk HPV of 3.17-fold from 5.7% in 2011 to 18.1% in
2019 - with the coefficient of determination or R2 = 0.764, suggesting a strong, positive
correlation between more recent sample years and HPV-positive results.

Raw data for HPV-positive and HPV-negatives samples from this screening was compiled
(Table 3). These data demonstrate an average sample number of approximately 116 per year,
ranging between n=65 (2015) and n=229 (2018) for the lowest and highest, respectively. The
total number of HPV-positive samples was N=133 and HPV-negative samples was N=806, with
a total sample number of N=930.
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Table 3. qPCR HPV screening by year.

Year

HPV-positive

HPV-negative

Total sample

Proportion of

samples

samples

number

HPV-positives

2011

n=5

n=82

n=87

0.057

2012

n=15

n=137

n=152

0.099

2013

n=11

n=67

n=78

0.141

2014

n=21

n=112

n=133

0.158

2015

n=13

n=52

n=65

0.200

2016

n=13

n=74

n=87

0.176

2018

n=40

n=199

n=229

0.202

2019

n=15

n=83

n=98

0.181

Total

N=133

N=806

N=930

To assess whether the temporal association between sampling year and proportion of HPVpositive samples was restricted to adult samples, pediatric samples or found within both
populations - these data were analyzed separately (Figure 2). For example, analysis of the
pediatric sample data revealed an increase of 61.5% between 2012 (11.9%) and 2019 (19.5%).
Analysis of the coefficient of determination or R2 = 0.671, which suggests this population subgroup exhibits a positive correlation between the more recent sample years and HPV-positivity
(Fig. 2A). In addition, analysis of the adult sample data revealed an increase of 6.42-fold
between 2011 (4.7%) and 2018 (30.2%). The coefficient of determination or R2 = 0.934, which

29

suggests a very high correlation between the year of sampling and proportion of HPV-positive
samples (Fig. 2B).

A

A
Figure 2. Prevalence of high-risk oral HPV increased over time among both pediatric and adult
samples. A) Analysis of pediatric samples revealed an increase of 61.5% between 2012 (11.9%)
and 2019 (19.5%) with a coefficient of determination or R2 = 0.671. B) Evaluation of adult
samples revealed an increase of 6.42-fold between 2011 (4.7%) and 2018 (30.2%) with R2 =
0.934.
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To determine if these observations of increasing oral HPV prevalence were more closely
associated with males or females, data from the pediatric and adult samples were sorted,
analyzed and graphed (Figure 3). This analysis demonstrated that increases in oral HPV were
found among both male and female pediatric patient samples, including the significant 40.4%
increase observed among males between 2012 (12.7%) and 2019 (16.5%), p=0.0018. A more
significant increase of 93.9% was observed among pediatric females between 2012 (10.7%) and
2019 (20.77%), p=0.00013 (Fig. 3A).

The analysis of adult male and female patient samples also revealed significant and dramatic
increases in oral HPV (Fig. 3B). In brief, the increase in oral HPV among adult males increased
from 5.5% in 2011 to 29.1% in 2018, an increase of more than 5.3-fold, p=0.0001. In addition,
the increase among adult females increased from 3.4% in 2011 to 32.72% in 2018, an increase of
more than 9.5-fold, p=0.00001.
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Figure 3. Analysis of oral HPV prevalence by sex. A) Prevalence of oral HPV significantly
increased among pediatric males (40.4%) between 2012-2019, p=0.0018 with higher increases
(93.9%) observed among pediatric females over the same interval, p=0.00013. Oral HPV among
adult males increased more than 5.3-fold, p=0.0001 between 2011 and 2018, with more than 9.5fold increases observed among adult females during the same time period, p=0.00001.
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Due to the increased prevalence of oral HPV observed among both pediatric and adult patient
samples, more detailed analyses were performed to determine if there were any changes in the
average age of these patients (Figure 4). This analysis demonstrates that the average age of
pediatric patients with oral HPV has decreased significantly from an average age of 16 years in
2012 to 14.81 in 2019, R2=0.6752 (Fig. 4A). However, the average age of adult patients testing
positive for oral HPV has increased significantly from an average of 20.8 years in 2011 to 28.9
years in 2018, R2=0.5458 (Fig. 4B).
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Figure 4. Analysis of average age of HPV-positive samples. A) Average age of pediatric
patients with oral HPV decreased from 16 years in 2012 to 14.81 in 2019, R2=0.6752. B)
Average age of adult patients with oral HPV has increased from 20.8 years in 2011 to 28.9 years
in 2018, R2=0.5458.
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To more accurately assess the changes in average age among the HPV-positive samples, the
average ages were compiled along with the age range from both pediatric and adult samples
(Table 4). These data demonstrated that not only has the average age decreased among pediatric
samples over time (16.0 years in 2012 to 14.81 years in 2019), but the age range has also
extended into lower ages from a more narrow range of 15 - 17 years in 2012 to 12 - 17 years
between 2016 and 2018. In contrast, the average age among adult samples has increased over
time from 20.8 years in 2011 to 28.9 years in 2018, which has also included an increase in the
age range from 18 - 26 years in 2011 to 18 - 49 years in 2018.
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Table 4. Age summary of HPV-positive samples

Year

Pediatric

Adult

2011

N/A

Average: 20.8 years
Range (18 - 26 years)

2012

2013

2014

2015

2016

2018

2019

Average: 16.0 years

Average: 26.25 years

Range (15 - 17 years)

Range (18 - 55 years)

Average: 16.0 years

Average: 21.3 years

Range (15 - 17 years)

Range (18 - 27 years)

Average: 15.7 years

Average: 26.9 years

Range (14 - 17 years)

Range (18 - 41 years)

Average: 15.6 years

Average: 29.1 years

Range (13 - 17 years)

Range (18 - 66 years)

Average: 14.3 years

Average: 34.3 years

Range (12 - 16 years)

Range (23 - 52 years)

Average: 14.68 years

Average: 28.9 years

Range (13 - 17 years)

Range (18 - 49 years)

Average: 14.81 years

N/A

Range (14 - 17 years)
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Discussion
The primary goal of this study was to determine if there were any changes in the prevalence of
oral HPV over time using an existing dental-school based saliva repository. This study
successfully identified nearly 1,000 samples collected over the past decade from both adult and
pediatric patients, which were successfully screened for the most commonly identified high-risk
HPV strains HPV16 and HPV18. These results revealed a positive increase over time in the
percentage of samples harboring oral HPV between 2011 and 2019 - observations that were
consistent among both pediatric and adult populations. These results support similar recent
observations that demonstrate significant and persistent increases in oral HPV infection with
high-risk strains, such as HPV16 and HPV18 [30,31].

These results provide support for other recent clinical observations, adding to the growing
scientific consensus that more information is needed to accurately determine the burden of oral
HPV infection among healthy populations [32,33]. Moreover, as vaccination controversy and
hesitancy appears to have increased with the SARS-CoV-2 pandemic and routine healthcare and
vaccinations have been delayed or postponed - more information regarding the incidence and
prevalence of oral HPV infection (especially among adolescents and youth) may be needed to
understand the scope of the problem at hand and potential costs of delay or inaction [34,35]. As
the potential public health and prevention benefits of early HPV vaccination of adolescents and
young adults have now become evident, concerted research efforts will be needed to provide
clear and accurate information about the increasing presence of oral HPV infection and the
potential impact of vaccine hesitancy and postponement - especially among pediatric patients
[36-38].
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Healthcare providers, including dentists and orthodontists, are rapidly becoming an increasingly
important part of public health efforts to increase vaccine awareness and knowledge - as well as
providing up-to-date information to counter misinformation and reduce beliefs in vaccine myths
[39-41]. As part of this effort, researchers from this group and others have recently sought to
determine knowledge gaps, awareness and beliefs among dental students and residents to
evaluate potential gaps and address vaccine concerns and hesitancy [42,43]. These studies
support a growing body of research that demonstrates dentists and other oral healthcare providers
are, in fact, willing to discuss HPV vaccination and participate in vaccine administration if they
are given sufficient information about the increasing prevalence and risks of oral HPV infection particularly among adolescent and young adult populations [44-46]. Given that some dental
specialists, such as Orthodontists, regularly visit with the at-risk groups identified in this study
including both pediatric (12 – 17 year old) and adult (18 – 24 year old) patients, novel pathways
for increasing vaccine knowledge and awareness and countering misinformation may be
developed to coincide with their frequent patient interactions [47, 48].

The results from this study provide critical information regarding temporal trends observed in
both pediatric and adult oral HPV infection over time, which is significant due the fact that only
three previous oral HPV studies have been conducted in this patient population - all of which
were cross-sectional, single time point screenings conducted between five and ten years ago [2729]. In fact, these observations regarding increases in oral HPV infection support other recent
observations regarding worsening trends in both oral health and cancer epidemiology in Nevada
that might be explained, in part, by these results [49,50]. Furthermore, as the age of oral HPV
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infection among pediatric patients appears to be decreasing over time within this patient
population, the importance of early intervention and pediatric vaccination becomes more evident.

Conclusions
Based upon this information, the results of this study have revealed the presence of temporal
changes and increased prevalence of oral HPV infection among both the pediatric and adult
patients over time. These data provide critical epidemiologic information that must be considered
as new guidelines and recommendations are made regarding which HPV vaccination education
and awareness programs are introduced to healthcare providers (including dentists) and the
specific populations, such as pediatric patients, that are most likely to benefit from these
interventions.
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Chapter 3
Summary and Conclusions:
The primary goal of this study was to determine if there were any changes in the prevalence of
oral HPV over time using an existing dental-school based saliva repository. This study
successfully identified nearly 1,000 samples collected over the past decade from both adult and
pediatric patients, which were successfully screened for the most commonly identified high-risk
HPV strains HPV16 and HPV18. These results revealed a positive increase over time in the
percentage of samples harboring oral HPV between 2011 and 2019 - observations that were
consistent among both pediatric and adult populations. These results support similar recent
observations that demonstrate significant and persistent increases in oral HPV infection with
high-risk strains, such as HPV16 and HPV18 [30,31].

These results provide support for other recent clinical observations, adding to the growing
scientific consensus that more information is needed to accurately determine the burden of oral
HPV infection among healthy populations [32,33]. Moreover, as vaccination controversy and
hesitancy appears to have increased with the SARS-CoV-2 pandemic and routine healthcare and
vaccinations have been delayed or postponed - more information regarding the incidence and
prevalence of oral HPV infection (especially among adolescents and youth) may be needed to
understand the scope of the problem at hand and potential costs of delay or inaction [34,35]. As
the potential public health and prevention benefits of early HPV vaccination of adolescents and
young adults have now become evident, concerted research efforts will be needed to provide
clear and accurate information about the increasing presence of oral HPV infection and the
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potential impact of vaccine hesitancy and postponement - especially among pediatric patients
[36-38].

Healthcare providers, including dentists and orthodontists, are rapidly becoming an increasingly
important part of public health efforts to increase vaccine awareness and knowledge - as well as
providing up-to-date information to counter misinformation and reduce beliefs in vaccine myths
[39-41]. As part of this effort, researchers from this group and others have recently sought to
determine knowledge gaps, awareness and beliefs among dental students and residents to
evaluate potential gaps and address vaccine concerns and hesitancy [42,43]. These studies
support a growing body of research that demonstrates dentists and other oral healthcare providers
are, in fact, willing to discuss HPV vaccination and participate in vaccine administration if they
are given sufficient information about the increasing prevalence and risks of oral HPV infection particularly among adolescent and young adult populations [44-46]. Given that some dental
specialists, such as Orthodontists, regularly visit with the at-risk groups identified in this study
including both pediatric (12 – 17 year old) and adult (18 – 24 year old) patients, novel pathways
for increasing vaccine knowledge and awareness and countering misinformation may be
developed to coincide with their frequent patient interactions [47, 48].

The results from this study provide critical information regarding temporal trends observed in
both pediatric and adult oral HPV infection over time, which is significant due the fact that only
three previous oral HPV studies have been conducted in this patient population - all of which
were cross-sectional, single time point screenings conducted between five and ten years ago [2729]. In fact, these observations regarding increases in oral HPV infection support other recent

54

observations regarding worsening trends in both oral health and cancer epidemiology in Nevada
that might be explained, in part, by these results [49,50]. Furthermore, as the age of oral HPV
infection among pediatric patients appears to be decreasing over time within this patient
population, the importance of early intervention and pediatric vaccination becomes more evident.

Based on the findings presented throughout this document, the null hypotheses can be
rejected and the alternative hypotheses can be accepted for research questions 1 and 2.

1. What is the prevalence of oral HPV among the pediatric patient population at UNLVSDM over time?
a. Alternative hypothesis (HA): Yes, oral HPV prevalence does change over time
among pediatric patients
2. What is the prevalence of oral HPV among the adult patient population at UNLV-SDM
over time?
a. Alternative hypothesis (HA): Yes, oral HPV prevalence does change over time
among adult patients

Limitations and Recommendations:
Although this study provides novel insights into this patient population, there are some
limitations to this study that must also be considered. First, this was a retrospective study of
previously collected saliva samples and is therefore cross-sectional in nature. No information is
available to determine how or when the patients became HPV-positive and whether this oral
infection was eventually cleared. Next, although each previous saliva-based study attempted to
reduce bias in sample collection, there was some evidence to suggest over sampling of minorities
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among the adult patient population. Future studies of this nature might include more rigorous
plans for randomized patient selection, which might reduce bias in the collection and subsequent
analysis of patient samples. Also, the patients’ existing vaccination statuses were not recorded
with the samples at the time of original collection, limiting the ability to directly assess the
relationship between vaccination and rising HPV prevalence and to understand the greater
implications surrounding vaccine hesitancy. Future research studies might include a more
detailed patient survey in order to draw more concrete connections between these two variables.
Furthermore, this study does not delve into the reasons why there may be increasing prevalence
among younger and younger pediatric patients – although some recent evidence has suggested
that increases in vaccine hesitancy and unfounded beliefs about general vaccine side effects and
vaccine safety concerns have recently reduced overall and HPV-specific vaccination rates [5155].

Additionally, while this retrospective study focused on the most commonly identified high risk
HPV strains responsible for the majority of cervical and oral cancer cases, specifically HPV16
and HPV18, the International Agency for Research on Cancer (IARC) has identified 10 other
high risk strains that also predispose patients to precancerous abnormalities and potential
malignancy. These strains include HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58, and HPV59 and are known to infect the oral cavity. Therefore, due to the
limited focus on HPV16 and HPV18, the true extent of oral HPV infection and exposure may be
unknown. For this reason, future studies to determine the incidence, prevalence, and range of
these overlooked oncogenic HPV strains are indicated. The studies should examine the various
strains as they relate to demographics, like age, race, and gender, and examine whether or not
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they are currently covered by the HPV vaccine. Future investigation into the strains that are often
omitted from HPV research can help to further identify at risk groups of individuals and may
even provide updated recommended age ranges for vaccination. Moreover, this research would
help in our understanding of cross protective antibodies against these strains given the HPV
vaccines currently available.

Overall, based upon this information, the results of this study have revealed the presence of
temporal changes and increased prevalence of oral HPV infection among both the pediatric and
adult patients over time. These data provide critical epidemiologic information that must be
considered as new guidelines and recommendations are made regarding which HPV vaccination
education and awareness programs are introduced to healthcare providers (including dentists)
and the specific populations, such as pediatric patients, that are most likely to benefit from these
interventions.
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